In general, patients with cancers limited to the primary tumor location (i.e., no lymph node involvement or distant metastasis, UICC stage I-II) showed a higher IL-22BP expression than patients in which the tumor had already spread to lymph nodes or distant organs (UICC stage III-IV, Figure 1D). This evidence concerns the gene IL22RA2 and neoplasm.